Therapy Overview & Search
This is the search page for all therapy, you can search for name or condition
Filter By
Therapeutic Area
Manufacturer
SORT BY
-
ibandronate
Ibandronate is a bisphosphonate medication that blocks the action of osteoclasts, cells responsible for bone breakdown, to strengthen bone and reduce the risk of fractures in post-menopausal women with osteoporosis.Manufacturer:MiscRoute of Administration:Oral, IntravenousSite of Care:OutpatientWebsite:Enrollment Forms:Synergen Prescription FormApproved Indication:
treatment and prevention of osteoporosis in postmenopausal women
Conditions:
- Osteoporosis
-
Ibsrela (tenapanor)
Ibsrela (tenapanor) inhibits an exchange protein in the lining of the colon and small intestine, increasing sodium and water excretion and softening stool to help improve constipation.Manufacturer:ArdelyxRoute of Administration:OralSite of Care:OutpatientWebsite:phone:844-427-7352Approved Indication:
treatment of irritable bowel syndrome with constipation in adults
Conditions:
- Irritable Bowel Syndrome with Constipation (IBS-C)
Therapeutic Area:
- Gastroenterology
-
Idacio (adalimumab-aacf)
Idacio (adalimumab-aacf) is an FDA-approved biosimilar to Humira. Like Humira, Idacio is a monoclonal antibody that blocks the action of TNF-alpha to reduce inflammation in rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and panuveitis.Manufacturer:Fresenius KabiRoute of Administration:SubcutaneousSite of Care:OutpatientWebsite:Approved Indication:
- reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis
- reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older
- reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis
- reducing signs and symptoms in adult patients with active ankylosing spondylitis
- treatment of moderately to severely active Crohn’s disease in adult patients
- treatment of moderately to severely active ulcerative colitis in adult patients
- treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate
- treatment of moderate to severe hidradenitis suppurativa in adult patients
- treatment of non-infectious intermediate, posterior, and panuveitis in adult patients
Conditions:
- Ankylosing Spondylitis
- Crohn’s Disease
- Hidradenitis Suppurativa
- Juvenile Idiopathic Arthritis
- Plaque Psoriasis
- Psoriatic Arthritis
- Rheumatoid Arthritis
- Ulcerative Colitis
- Uveitis
Therapeutic Area:
- Dermatology
- Gastroenterology
- Rheumatology
-
Imuldosa (ustekinumab-srlf)
Imuldosa (ustekinumab-srlf) is an FDA-approved biosimilar to Stelara. Like Stelara, Imuldosa is a monoclonal antibody that blocks the action of interleukins 12 and 23 to reduce inflammation in psoriatic arthritis, Crohn’s disease, ulcerative colitis, and plaque psoriasis.Manufacturer:Accord BioPharmaRoute of Administration:Intravenous, SubcutaneousSite of Care:OutpatientWebsite:Enrollment Forms:Synergen Prescription FormApproved Indication:
- treatment of adults and pediatric patients 6 years and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy
- treatment of active psoriatic arthritis in adults and pediatric patients 6 years and older
- treatment of moderately-to-severely active Crohn’s disease in adults
- treatment of moderately-to-severely active ulcerative colitis in adults
Conditions:
- Crohn’s Disease
- Plaque Psoriasis
- Psoriatic Arthritis
- Ulcerative Colitis
Therapeutic Area:
- Dermatology
- Gastroenterology
- Rheumatology
-
Imuran (azathioprine)
Imuran (azathioprine) is a prodrug of 6-mercaptopurine, a neucleoside metabolic inhibitor approved to prevent rejection of a transplanted organ or to reduce signs and symptoms of certain autoimmune disorders.Manufacturer:Sebela Pharmaceuticals Inc.Route of Administration:OralSite of Care:OutpatientWebsite:Enrollment Forms:Synergen Prescription FormApproved Indication:
- adjunct for the prevention of rejection in renal homotransplantation
- treatment of active rheumatoid arthritis to reduce signs and symptoms
Conditions:
- solid organ transplant
- rheumatoid arthritis
Therapeutic Area:
- Rheumatology
- Nephrology
- Solid Organ Transplant
-
Inflectra (infliximab-dyyb)
Inflectra (infliximab-dyyb) is the first FDA-approved biosimilar to Remicade. Like Remicade, Inflectra is a monoclonal antibody that blocks the action of TNF-alpha to reduce inflammation in rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis.Manufacturer:PfizerRoute of Administration:IntravenousSite of Care:OutpatientWebsite:phone:1-844-722-6672Approved Indication:
- reducing signs and symptoms and inducing and maintaining clinical remission in adults or pediatric patients 6 years of age and older with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy
- reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing Crohn’s disease
- reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult or pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy
- [in combination with methotrexate] reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis
- reducing signa and symptoms in adult patients with active ankylosing spondylitis
- reducing signa and symptoms of active psoriatic arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients
- treatment of adult patients with chronic severe plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate
Conditions:
- Ankylosing Spondylitis
- Crohn’s Disease
- Plaque Psoriasis
- Psoriatic Arthritis
- Rheumatoid Arthritis
- Ulcerative Colitis
Therapeutic Area:
- Dermatology
- Gastroenterology
- Rheumatology
-
Injectafer (ferric carboxymaltose)
Injectafer (ferric carboxymaltose) is an iron infusion used to treat anemia by supporting the formation of hemoglobin.Manufacturer:Daiichi-SankyoRoute of Administration:IntravenousSite of Care:OutpatientWebsite:Approved Indication:
- treatment of iron deficiency anemia in adult and pediatric patients 1 year of age and older who have either intolerance or an unsatisfactory response to oral iron
- treatment of iron deficiency anemia in adult patients with non-dialysis dependent chronic kidney disease
- treatment of iron deficiency in adult patients with heart failure and New York Heart Association class II/III to improve exercise capacity
Conditions:
- Iron Deficiency Anemia
Therapeutic Area:
- Nephrology
-
Ixifi (infliximab-qbtx)
Ixifi (infliximab-qbtx) is an FDA-approved biosimilar to Remicade. Like Remicade, Ixifi is a monoclonal antibody that blocks the action of TNF-alpha to reduce inflammation in rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis.Manufacturer:PfizerRoute of Administration:IntravenousSite of Care:OutpatientWebsite:Enrollment Forms:Synergen Prescription FormApproved Indication:
- reducing signs and symptoms and inducing and maintaining clinical remission in adults or pediatric patients 6 years of age and older with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy
- reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing Crohn’s disease
- reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult or pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy
- [in combination with methotrexate] reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis
- reducing signa and symptoms in adult patients with active ankylosing spondylitis
- reducing signa and symptoms of active psoriatic arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients
- treatment of adult patients with chronic severe plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate
Conditions:
- Ankylosing Spondylitis
- Crohn’s Disease
- Plaque Psoriasis
- Psoriatic Arthritis
- Rheumatoid Arthritis
- Ulcerative Colitis
Therapeutic Area:
- Dermatology
- Gastroenterology
- Rheumatology
-
Jadenu (deferasirox)
Jadenu (deferoxamine) is an iron-chelating agent given orally to lower iron levels in the blood. It is available as film-coated tablets or sprinkle granules.Manufacturer:NovartisRoute of Administration:OralSite of Care:OutpatientWebsite:Enrollment Forms:Synergen Prescription FormApproved Indication:
- treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older
- treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia syndromes and with a liver iron (Fe) concentration of at least 5mg Fe per gram of dry weight and a serum ferritin greater than 300mcg/L
Conditions:
- Sickle Cell Disease
- Anemia
- Non-Transfusion-Dependent Thalassemia
Therapeutic Area:
- Oncology
-
Jascayd (nerandomilast)
Jascayd (nerandomilast) is an inhibitor of the enzyme phosphodiesterase 4 (PDE4), an important contributor to inflammation and fibrosis. By blocking the action of PDE4, Jascayd can slow the development of new pulmonary fibrosis.Manufacturer:Boehringer IngelheimRoute of Administration:OralSite of Care:OutpatientWebsite:Approved Indication:
treatment of adult patients with idiopathic pulmonary fibrosis
Conditions:
- Idiopathic Pulmonary Fibrosis
-
Jubbonti (denosumab-bbdz)
Jubbonti (denosumab-bbdz) is an FDA-approved interchangeable biosimilar to Prolia. Like Prolia, Jubbonti is a monoclonal antibody that blocks the action of the protein RANKL to decrease bone breakdown.Manufacturer:SandozRoute of Administration:SubcutaneousSite of Care:OutpatientWebsite:phone:1-800-954-9128Approved Indication:
- treatment of postmenopausal women with osteoporosis at high risk for fracture
- to increase bone mass in men with osteoporosis at high risk for fracture
- treatment of glucocorticoid-induced osteoporosis in men and women at high risk for fracture
- to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer
- to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer
Conditions:
- Osteoporosis
Therapeutic Area:
- Endocrinology
- Geriatrics
- Oncology
-
Linzess (linaclotide)
Linzess (linaclotide) is a secretagogue approved by the FDA to increase the amount of water in the intestines to improve constipation and decrease abdominal pain.Manufacturer:AbbVie | Ironwood PharmaceuticalsRoute of Administration:OralSite of Care:OutpatientWebsite:Enrollment Forms:Synergen Prescription FormApproved Indication:
- treatment of irritable bowel syndrome with constipation in adults
- treatment of chronic idiopathic constipation in adults
- treatment of functional constipation in pediatric patients 6 to 17 years of age
Conditions:
- Irritable Bowel Syndrome with Constipation (IBS-C)
- Chronic Idiopathic Constipation (CIC)
- Functional Constipation
Therapeutic Area:
- Gastroenterology